紫杉醇脂质体联合顺铂治疗晚期非小细胞肺癌的临床观察

Clinical Observation of Paclitaxel Liposome Combined with Cisplatin in the Treatment of Advanced Non-small-cell Lung Cancer

目的评价紫杉醇脂质体联合顺铂治疗晚期非小细胞肺癌的临床疗效和不良反应。方法紫杉醇脂质体(135mg/m2,静脉滴注3h,第1天)联合顺铂(25mg/m2,静脉滴注,第1～3天)治疗,每21天为1个周期,每化疗2个周期按RECIST标准评价疗效。结果全组43例患者共接受138个周期化疗,CR0例,PR16例,SD20例,PD7例,总有效率为37.2%,不良反应主要为骨髓抑制、胃肠道反应、周围神经毒性。骨髓抑制以白细胞减少为主,Ⅲ～Ⅳ级发生率为32.6%,胃肠道反应及周围神经毒性症状均较轻,全组无过敏反应发生,无治疗相关性死亡。结论紫杉醇脂质体联合顺铂治疗晚期非小细胞肺癌的疗效确切,不良反应轻,值得临床推广。

Objective To evaluate the efficacy and toxity of paclitaxel liposome plus cisplatine in the treatment of advanced non-small cell lung cancer.Methods Paclitaxel liposome 135 mg/m2 as a 3h infusion on day 1 and cisplatine 25 mg/m2 as a infusion on day 1 to 3.Treatment was repeated every 21 day.Treatment efficacy was evaluated every two cycles based on the RESIST standard.Results Patients received total of 138 cycles of treatment.The overall response rate was 37.2%,no case achieved complete responces,16 achieved partial responces,20 had stable disease,7 had progression disease.Main adverse reactions were myelosuppression,gastrointestinal toxicity and peripheral neuropathy.the primary myelosuppression was hypoleukia and 3~4 grade rate was 32.6%.The gastrointestinal and peripheral toxicity were mild.No occurrence of hypersensitivity and treatment related death.Conclusion Paclitaxel liposome plus cisplatine regimen is effective and well tolerated in patients with advanced non-small cell lung cancer.